ID

37402

Description

Vildagliptin Versus Dapagliflozin on Glucagon; ODM derived from: https://clinicaltrials.gov/show/NCT02475070

Lien

https://clinicaltrials.gov/show/NCT02475070

Mots-clés

Versions (1)
  1. 23/07/2019 23/07/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

23 juillet 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes NCT02475070

Anglais

Eligibility Type 2 Diabetes NCT02475070

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. written consent has been given.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
2. patients with type 2 diabetes treated with a stable dose of metformin during the last three months
Description

Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
3. age 20-70 years.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
4. hba1c 6.5-8.5% (48-67 mmol/mol) at visit 1.
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
5. ability to complete the study
Description

Completion of clinical trial Able

Type de données

boolean

Alias
UMLS CUI [1,1]
C2732579
UMLS CUI [1,2]
C0085732
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. use of other glucose-lowering therapy than metformin within three months prior to visit 1.
Description

Hypoglycemic Agents | Exception Metformin

Type de données

boolean

Alias
UMLS CUI [1]
C0020616
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
2. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly.
Description

Secondary diabetes mellitus | Cushing Syndrome | Acromegaly

Type de données

boolean

Alias
UMLS CUI [1]
C0271640
UMLS CUI [2]
C0010481
UMLS CUI [3]
C0001206
3. type 1 diabetes, positive gad antibodies
Description

Diabetes Mellitus, Insulin-Dependent | Anti-GAD antibody positive

Type de données

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C1167896
4. estimated glomerular filtration rate <60 ml/min
Description

Estimated Glomerular Filtration Rate

Type de données

boolean

Alias
UMLS CUI [1]
C3811844
5. acute infections which may affect blood glucose control within 4 weeks prior to visit 1
Description

Communicable Diseases Affecting Blood Glucose Control

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0005802
UMLS CUI [1,4]
C0243148
6. any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
Description

Hypoglycaemic episode Recurrent | Hypoglycaemic episode Severe

Type de données

boolean

Alias
UMLS CUI [1,1]
C0745153
UMLS CUI [1,2]
C2945760
UMLS CUI [2,1]
C0745153
UMLS CUI [2,2]
C0205082
7. any history of acute pancreatitis
Description

Pancreatitis

Type de données

boolean

Alias
UMLS CUI [1]
C0030305
8. any history of anaphylaxis, angioedema, and exfoliative skin conditions including stevens-johnson syndrome.
Description

Anaphylaxis | Angioedema | Skin condition Exfoliative | Stevens-Johnson Syndrome

Type de données

boolean

Alias
UMLS CUI [1]
C0002792
UMLS CUI [2]
C0002994
UMLS CUI [3,1]
C1719933
UMLS CUI [3,2]
C0205226
UMLS CUI [4]
C0038325
9. liver disease such as cirrhosis or chronic active hepatitis
Description

Liver disease | Liver Cirrhosis | Hepatitis, Chronic

Type de données

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C0023890
UMLS CUI [3]
C0019189
10. history of coronary heart disease or heart failure class iii or iv
Description

Coronary heart disease | Heart failure New York Heart Association Classification

Type de données

boolean

Alias
UMLS CUI [1]
C0010068
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
11. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
Description

Blood Donation Unit Quantity | Blood Loss Unit Quantity | Blood Transfusion

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005794
UMLS CUI [1,2]
C0439148
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C3163616
UMLS CUI [2,2]
C0439148
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0005841
12. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
Description

Growth hormone treatment | Steroid therapy oral chronic | Steroid therapy parenteral chronic

Type de données

boolean

Alias
UMLS CUI [1]
C0744483
UMLS CUI [2,1]
C0149783
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205191
UMLS CUI [3,1]
C0149783
UMLS CUI [3,2]
C1518896
UMLS CUI [3,3]
C0205191
13. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
Description

Investigational New Drugs Inappropriate Clinical Trial

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0008976
14. hypersensitivity to vildagliptin or dapagliflozin or any compound in the tablet core
Description

Hypersensitivity Vildagliptin | Hypersensitivity Dapagliflozin | Hypersensitivity Compound Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1570906
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C2353951
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1706082
UMLS CUI [3,3]
C0013230
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes NCT02475070

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. written consent has been given.
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable
Item
2. patients with type 2 diabetes treated with a stable dose of metformin during the last three months
boolean
C0011860 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Age
Item
3. age 20-70 years.
boolean
C0001779 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
4. hba1c 6.5-8.5% (48-67 mmol/mol) at visit 1.
boolean
C0474680 (UMLS CUI [1])
Completion of clinical trial Able
Item
5. ability to complete the study
boolean
C2732579 (UMLS CUI [1,1])
C0085732 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Hypoglycemic Agents | Exception Metformin
Item
1. use of other glucose-lowering therapy than metformin within three months prior to visit 1.
boolean
C0020616 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
Secondary diabetes mellitus | Cushing Syndrome | Acromegaly
Item
2. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly.
boolean
C0271640 (UMLS CUI [1])
C0010481 (UMLS CUI [2])
C0001206 (UMLS CUI [3])
Diabetes Mellitus, Insulin-Dependent | Anti-GAD antibody positive
Item
3. type 1 diabetes, positive gad antibodies
boolean
C0011854 (UMLS CUI [1])
C1167896 (UMLS CUI [2])
Estimated Glomerular Filtration Rate
Item
4. estimated glomerular filtration rate <60 ml/min
boolean
C3811844 (UMLS CUI [1])
Communicable Diseases Affecting Blood Glucose Control
Item
5. acute infections which may affect blood glucose control within 4 weeks prior to visit 1
boolean
C0009450 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005802 (UMLS CUI [1,3])
C0243148 (UMLS CUI [1,4])
Hypoglycaemic episode Recurrent | Hypoglycaemic episode Severe
Item
6. any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
boolean
C0745153 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
C0745153 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
Pancreatitis
Item
7. any history of acute pancreatitis
boolean
C0030305 (UMLS CUI [1])
Anaphylaxis | Angioedema | Skin condition Exfoliative | Stevens-Johnson Syndrome
Item
8. any history of anaphylaxis, angioedema, and exfoliative skin conditions including stevens-johnson syndrome.
boolean
C0002792 (UMLS CUI [1])
C0002994 (UMLS CUI [2])
C1719933 (UMLS CUI [3,1])
C0205226 (UMLS CUI [3,2])
C0038325 (UMLS CUI [4])
Liver disease | Liver Cirrhosis | Hepatitis, Chronic
Item
9. liver disease such as cirrhosis or chronic active hepatitis
boolean
C0023895 (UMLS CUI [1])
C0023890 (UMLS CUI [2])
C0019189 (UMLS CUI [3])
Coronary heart disease | Heart failure New York Heart Association Classification
Item
10. history of coronary heart disease or heart failure class iii or iv
boolean
C0010068 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
Blood Donation Unit Quantity | Blood Loss Unit Quantity | Blood Transfusion
Item
11. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
boolean
C0005794 (UMLS CUI [1,1])
C0439148 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3163616 (UMLS CUI [2,1])
C0439148 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0005841 (UMLS CUI [3])
Growth hormone treatment | Steroid therapy oral chronic | Steroid therapy parenteral chronic
Item
12. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
boolean
C0744483 (UMLS CUI [1])
C0149783 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205191 (UMLS CUI [2,3])
C0149783 (UMLS CUI [3,1])
C1518896 (UMLS CUI [3,2])
C0205191 (UMLS CUI [3,3])
Investigational New Drugs Inappropriate Clinical Trial
Item
13. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
boolean
C0013230 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
Hypersensitivity Vildagliptin | Hypersensitivity Dapagliflozin | Hypersensitivity Compound Investigational New Drugs
Item
14. hypersensitivity to vildagliptin or dapagliflozin or any compound in the tablet core
boolean
C0020517 (UMLS CUI [1,1])
C1570906 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C2353951 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C1706082 (UMLS CUI [3,2])
C0013230 (UMLS CUI [3,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial